Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Merck : Chelmsford High School Students explore life sciences careers

share with twitter share with LinkedIn share with facebook
share via e-mail
12/08/2016 | 10:45pm CET

EMD Serono hosted 30 students from Chelmsford High School as part of Career Exploration Day organized by the MassBioEd Foundation.

“All of us at EMD Serono are excited to welcome the students to our Research & Development Facility in Billerica for the opportunity to tour our labs and speak with our researchers and scientists about the work they do every day to accelerate innovation,” said Gary Zieziula, president and managing director of EMD Serono.

Career Exploration Days provide students with the opportunity to learn about the biotechnology industry, interact directly with life sciences professionals, participate in science demonstrations and tour company facilities. At these events, students experience a tangible connection between the life sciences curriculum they see in their classrooms and the groundbreaking scientific innovation that drives the Massachusetts life sciences supercluster.

Career Exploration Day, part of MassBioEd’s signature BioTeach program, aims to increase students’ interest in pursuing life sciences careers. Through BioTeach, MassBioEd provides teacher professional development workshops and mentoring, student experiential learning and career exploration opportunities, and funds to public schools for lab supplies and equipment.

For information: massbioed.org.

© Copyright, 2016 Chelmsford Independent. All Rights Reserved., source Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
12/08 MERCK : Chelmsford High School Students explore life sciences careers
12/08 BIOCARTIS GROUP NV : Biocartis launches second liquid biopsy assay - Assay co-de..
12/06 MERCK : Consumer Health business drives consumer-centric, purposeful innovation
12/06 MERCK : s Consumer Health Business Drives Consumer-Centric, Purposeful Innovatio..
12/05 RONASTAR® RED ALLURE : The elegant, matte pigment innovation from Merck
12/05 MERCK : to Provide Provantage® End-to-End Services to Acticor Biotech SAS
12/02 MERCK : Launches Parteck® MXP Excipient for Increased Solubility
12/01 MERCK : Expands Distribution Agreement with Roche
12/01 QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck ..
12/01 DGAP-PVR : Merck KGaA: Release according to Article 26, Section 1 of the WpHG w..
More news
Sector news : Specialty & Advanced Pharmaceuticals
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
12/07DJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
12/01 Roche expands distribution partnership with Merck KGaA
11/30 Evotec and Merck KGaA team up to discover new therapeutic targets
11/29 FDA accepts avelumab BLA under Priority Review for rare type of skin cancer
11/22 QuintilesIMS forms collaboration with major drug firms to better understand r..
11/15 Merck KGaA 2016 Q3 - Results - Earnings Call Slides
Financials (€)
Sales 2016 15 095 M
EBIT 2016 3 561 M
Net income 2016 1 782 M
Debt 2016 11 024 M
Yield 2016 1,37%
P/E ratio 2016 21,66
P/E ratio 2017 20,49
EV / Sales 2016 1,52x
EV / Sales 2017 1,35x
Capitalization 11 883 M
More Financials
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 107 €
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA2.65%12 822
ABBVIE INC4.02%97 490
KYOWA HAKKO KIRIN CO L..-20.26%7 799
More Results